卢敏课题组
上海交通大学医学院附属瑞金医院上海血液学研究所
组学与疾病全国重点实验室（原医学基因组学国家重点实验室）
卢敏课题组
上海交通大学医学院附属瑞金医院上海血液学研究所
组学与疾病全国重点实验室（原医学基因组学国家重点实验室）
上海交通大学医学院附属瑞金医院上海血液学研究所
组学与疾病全国重点实验室（原医学基因组学国家重点实验室）
上海交通大学医学院附属瑞金医院上海血液学研究所
组学与疾病全国重点实验室（原医学基因组学国家重点实验室）
[1] Wu J, Song H, …, M Lu#. Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies. Nat Rev Cancer. 2025 May 16. doi: 10.1038/s41568-025-00826-7.
[2] Xiao S, F Shi, …, M Lu#. Characterization of the generic mutant p53-rescue compounds in a broad range of assays. Cancer Cell, 2024, 42(3): 325-327 .
[3] Song H, S Xiao, …, M Lu#. Drugging p53: Barriers, Criteria, and Prospects. Cancer Discov, 2024, 14(11): 2055-2060 .
[4] Song H, J Wu, …, M Lu#. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Science Translational Medicine, 2023, 15(690): eabn9155 .
[5] Chen S, J.-L Wu, …, M Lu#. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell, 2021, 39(2): 225-239.e8 .
[6] M Lu, M R. …, X Lu. Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding. Nature Reviews Molecular Cell Biology, 2016, 17(8): 523-532 .
[7] M Lu, J Zak, …, X Lu. A Code for RanGDP Binding in Ankyrin Repeats Defines a Nuclear Import Pathway. Cell, 2014, 157(5): 1130-1145 .
[8] M Lu, H Breyssens, …, X Lu. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell. 2013, 23(5): 618-633 .
[9] Liang Y, An Q, …,M Lu#. AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity. J Med Chem. 2023 Dec 28;66(24):16579-16596 .
[10] Wang Z, Zhao Y,…,M Lu#. Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro. Signal Transduct Target Ther. 2021 Jun 1;6(1):214.
[1] Li J, Zhang S,…, M Lu#. Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses. Cell Rep Med. 2025 Feb 12:101976.
[2] Wang H, Wang Z,…, M Lu#. Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study. Front Med. 2024 Apr;18(2):357-374.
[3] Liang Y, An Q,…, M Lu#. AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity. J Med Chem. 2023 Dec 28;66(24):16579-16596.
[4] Li J, Xiao S ,…, M Lu#. Arsenic trioxide extends survival of Li-Fraumeni syndrome mimicking mouse. Cell Death Dis. 2023 Nov 29;14(11):783.
[5] Yan N, Li Y,…, M Lu#. Developmental arsenic exposure impairs cognition, directly targets DNMT3A, and reduces DNA methylation. EMBO Rep. 2022 Jun 7;23(6):e54147.
[6] Tang Y, Song H,…, M Lu#. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Rep. 2022 Apr 12;39(2):110622.
[7] Wu JL, Chen S, M Lu#. Broad-spectrum rescue compounds for structural p53 mutations: perspective on ‘Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site’. Mol Cell Biol. 2021 May 7;13(2):155-157.
[8] Wu, J, Song, H,…, M Lu#. Three optimized assays for the evaluation of compounds that can rescue p53 mutants. STAR Protoc. 2021 Jul 27;2(3):100688.
[9] Wu J, Li Y,…, M Lu#. Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells. Clin Transl Med. 2021 Nov;11(11):e593.
[10] Wang Z, Zhao Y ,…, M Lu#. Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M(pro). Signal Transduct Target Ther. 2021 Jun 1;6(1):214.
[11] Wu J, Liang Y,…, M Lu#. CDK9 inhibitors reactivate p53 by downregulating iASPP. Cell Signal. 2020 Mar;67:109508.
[12] Yang H, Xia L,…, Ma Y#. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nature medicine 25, 1428-1441.
[13] Chen S, Wu J,…, Lu X. iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition. Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17470-17479.
[14] M Lu, Muers MR,…, Lu, X. Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding. Nat Rev Mol Cell Biol. 2016 Aug;17(8):523-32.
[15] Lu M, Gong X,…, Pan Y. Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells. J Biol Chem. 2006 May 12;281(19):13620-13627.
[16] 吴嘉祺, 卢敏, 老药新用：三氧化二砷修复p53结构型突变. 生命的化学 41, 202-206
[17] Qin Y, Dai W,…, M Lu#. Fe-SOD cooperates with Nutlin3 to selectively inhibit cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 2013 Feb 8;431(2):169-75.
1.专家共识：ATO靶向p53治疗方案形成中国抗癌学会中国专家共识 ：中国实用儿科杂志，2025, 40(4）,271-283。
2.临床试验：ATO靶向p53治疗方案进入6项ClinicalTrials注册的临床试验：https://clinicaltrials.gov/search?cond=arsenic%20p53。
3.临床建议：在TP53 Trust提出ATO靶向p53治疗方案的临床建议http://tp53.co.uk/interview-with-min-lu/。
4.临床建议：AntiCancer介绍ATO靶向p53治疗方案https://www.anticancerfund.org/en/blog/latest-news-about-drug-repurposing-oncology-4。
5.专利转化：p53恢复剂专利（PCT/CN2018/085190）进入中国、美国、欧盟、日本、澳大利亚、加拿大等全球主要国家，完成高水平转化。
6.专利转化：p53恢复剂专利（PCT/CN2019/070117）进入中国、美国、欧盟、日本、澳大利亚、加拿大等全球主要国家，完成高水平转化。
7.工业界转化：设计新结构p53恢复剂AcGlcAs，并在国内外供基础研究和临床前研究使用（MedKoo货号: 125762）。
医学基因组学国家重点实验室
卢敏课题组（卢敏实验室）©️版权所有